← Evidence map

ArticleClinical Medicine Insights. Oncology2025

Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Reechashree Dhungana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | OpenQuestion